Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, providing rapid relief and safety by blocking bradykinin‑mediated vascular permeability.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards and ensure consistent product integrity throughout the supply chain.

Icatibant Zentiva is used to treat conditions driven by excessive bradykinin activity, primarily hereditary angioedema. - Hereditary angioedema type I: rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: rapid reduction of swelling during acute attacks. - Acute hereditary angioedema attacks: alleviates symptoms and shortens attack duration.

Icatibant Zentiva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort. - Redness or swelling at injection site: localized erythema. - Nausea: transient queasiness. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring emergency care. - Hypotension: sudden drop in blood pressure. - Angioedema: swelling of face, lips, or airway.

When using Icatibant Zentiva, several precautions should be observed to ensure safe and effective therapy. - Confirm diagnosis: verify hereditary angioedema before initiating treatment. - Monitor for hypersensitivity: discontinue if signs of severe allergic reaction appear. - Cardiovascular caution: observe blood pressure in patients with known heart disease. - Avoid in known hypersensitivity: do not use if patient is allergic to icatibant or formulation components. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Zentiva can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - Renin‑angiotensin system blockers: similar potential to exacerbate bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may influence hereditary angioedema severity. - Other B2 receptor antagonists: additive pharmacologic effect, use with caution. - Immunosuppressants: monitor for infection risk while on therapy.